Fludarabine
CNS 2a
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the CNS 2a cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM National Cancer Institute (NCI) | Phase 1 | CC |
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 1 | CC |
Cediranib National Cancer Institute (NCI) | Phase 1 | CC |
AZD1775 National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →